Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Users Online: 5544 | Home Print this page Email this page Small font size Default font size Increase font size
Year : 2012  |  Volume : 32  |  Issue : 5  |  Page : 57

PA01.08. An evaluation of a new anti-aids herbo-mineral compound (laa-1)

1 Lavanya Ayurvedic Pvt. Ltd., Near Chattarpur Mandir, Delhi-110074, India
2 Lavanya Ayurvedic Pvt. Ltd., Biotech Park, Lucknow, U.P.-21, India
3 Lavanya Ayurvedic Hospital & Research centre for Cancer & AIDS, Dhawa Estate, Near Telco, Lucknow, U.P., India

Correspondence Address:
Pushpendra Shukla
Lavanya Ayurvedic Pvt. Ltd., Near Chattarpur Mandir, Delhi-110074
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Purpose: AIDS is the deadliest disease of the decade, for which unfortunately even after several advancement in biomedical sciences, no curative treatment is available as no drug is capable of separating and recovering the motif between retro viral DNA of the host. Method: The present study has been undertaken to evaluate the role of a new herbo mineral compound (LAA01) in 18 cases suffering from AIDS after getting clearance from the Institutional Ethical committee (IEC). Criteria for assessing antiviral activity includes CD3, CD4, CD8, CD4/ CD8 ratio and viral load parameters were measured. These parameters were conducted at Biognosis an approved GLP lab in Hyderabad. Result: Pre treatment mean values of these parameters compared with LAA01 treated cases values periodically respectively given in following table. The results indicate a significant rise in CD4 counts and a significant decrease in viral load. Conclusion: It concludes that the drug Ayurvedic herbo mineral preparation LAA01 under test is not only a viridicidal (drug inhibiting the HIV replication) as is evident from decrease in HIV load, but the drug also enhanced immunity as is evident from increases in CD4 and CD8 counts and their respective percentage, which maintained the quality of life (QOL) of the patients, which needs further extensive clinical trial.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal